42. The composition of claim 41, wherein the pharmaceutically acceptable carrier is selected from the group consisting of binders, buffering agents, coloring agents, diluents, disintegrants, emulsifiers, flavorants, glidants, lubricants, preservatives, stabilizers, surfactants, tableting agents, and wetting agents, and combinations thereof.

43. Use of a therapeutically effective amount of a compound of any one of claims 21, 25, 34 or 38 in the manufacture of a medicament for treating or diagnosing cancer in a mammal,

wherein the medicament is to be administered optionally combined with one or more additional active ingredients.

44. The use of claim 43, wherein the one or more additional active ingredients include additional therapeutic compounds, including anticancer therapeutic compounds such as doxorubicin, paclitaxel, docetaxel, cisplatin, camptothecin, temozolomide, avastin, Herceptin, Erbitux, and combinations thereof.

45. The compound of claim 16 wherein $R_{14}$ is



.

46. The compound of claim 28 wherein $R_{14}$ is